8-K Announcements
6Material company update
Mar 31, 2026·SEC
Material company update
Mar 10, 2026·SEC
Material company update
Jan 13, 2026·SEC
Co-Diagnostics, Inc.(CODX)Earnings, Financials & Key Ratios
CODX•NASDAQ
$1.93
$2M mkt cap·Price updated May 7, 2026
AboutCo-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Show more
- Revenue$622K-84.1%
- EBITDA-$30M+22.0%
- Net Income-$47M-24.6%
- EPS (Diluted)-35.25+5.2%
- Gross Margin64.28%-13.7%
- EBITDA Margin-4847.72%-390.4%
- Operating Margin-5025.53%-390.9%
- Net Margin-7533.62%-683.6%
- ROE-125.16%-133.3%
- ROIC-73.89%-56.8%
- Debt/Equity0.06+51.3%
CODX Key Insights
Co-Diagnostics, Inc. (CODX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 98 (top 2%)
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Sales declining 61.6% over 5 years
- ✗Shares diluted 31.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CODX Price & Volume
Co-Diagnostics, Inc. (CODX) stock price & volume — 10-year historical chart
Loading chart...
CODX Growth Metrics
Co-Diagnostics, Inc. (CODX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years51.15%
5 Years-61.6%
3 Years-73.7%
TTM-83.18%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-24.59%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM3.37%
Return on Capital
10 Years-234.3%
5 Years-30.67%
3 Years-58.68%
Last Year-80.33%
CODX Recent Earnings
Co-Diagnostics, Inc. (CODX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 3/12 qtrs (25%)
Q4 2025Latest
Nov 13, 2025EPS
$4.80
Est $5.71
+15.9%
Revenue
$145,380
Est $126,000
+15.4%
Q3 2025
Aug 14, 2025EPS
$0.23
Est $0.25
+8.0%
Revenue
$162,910
Est $300,000
-45.7%
Q2 2025
May 8, 2025EPS
$0.24
Est $0.33
+27.3%
Revenue
$50,277
Est $187,500
-73.2%
Q2 2025
Mar 27, 2025EPS
$0.36
Est $0.34
-5.9%
Revenue
$149,325
Est $375,000
-60.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 13, 2025 | $4.80vs $5.71+15.9% | $145,380vs $126,000+15.4% |
| Q3 2025 | Aug 14, 2025 | $0.23vs $0.25+8.0% | $162,910vs $300,000-45.7% |
| Q2 2025 | May 8, 2025 | $0.24vs $0.33+27.3% | $50,277vs $187,500-73.2% |
| Q2 2025 | Mar 27, 2025 | $0.36vs $0.34-5.9% | $149,325vs $375,000-60.2% |
Based on last 12 quarters of dataView full earnings history →
CODX Peer Comparison
Co-Diagnostics, Inc. (CODX) competitors in Device suppliers, distribution, and services — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 QDEL | 733.24M | 10.77 | -0.65 | -1.89% | -45.57% | -56.31% | 1.46 | |
 FLGT | 449.48M | 15.11 | -7.67 | 13.83% | -18.75% | -5.42% | 0.00 | |
 CLOV | 1.44B | 2.82 | -16.59 | 40.34% | -2.58% | -17.08% | ||
 NVAX | 1.5B | 9.23 | 3.63 | 64.69% | -14.73% | |||
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 IDXX | 45.45B | 572.20 | 43.75 | 10.42% | 24.63% | 70.87% | 0.67 | |
 NEOG | 2.01B | 9.25 | -1.84 | -3.2% | -68.47% | -28.64% | 0.44 | |
 CHEK | 12.17M | 2.08 | -0.48 | -226.19% |
Compare CODX vs Peers
Co-Diagnostics, Inc. (CODX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CODX Income Statement
Co-Diagnostics, Inc. (CODX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 7.66K | 39.91K | 214.97K | 74.55M | 97.89M | 34.22M | 6.81M | 3.92M | 622.49K |
| Revenue Growth % | - | 420.9% | 438.63% | 34579.9% | 31.3% | -65.04% | -80.09% | -42.53% | -84.1% |
| Cost of Goods Sold | 302 | 9.39K | 112.43K | 16.59M | 11.57M | 5.48M | 4.18M | 999.12K | 222.38K |
| COGS % of Revenue | 3.94% | 23.53% | 52.3% | 22.25% | 11.82% | 16.02% | 61.43% | 25.52% | 35.72% |
| Gross Profit | 7.36K▲ 0% | 30.52K▲ 314.7% | 102.54K▲ 236.0% | 57.96M▲ 56424.0% | 86.31M▲ 48.9% | 28.74M▼ 66.7% | 2.63M▼ 90.9% | 2.92M▲ 11.0% | 400.11K▼ 86.3% |
| Gross Margin % | 96.06% | 76.47% | 47.7% | 77.75% | 88.17% | 83.98% | 38.57% | 74.48% | 64.28% |
| Gross Profit Growth % | 119.63% | 314.67% | 235.99% | 56424.01% | 48.91% | -66.7% | -90.86% | 11% | -86.28% |
| Operating Expenses | 4.57M | 6.15M | 6M | 16.27M | 40.25M | 55.72M | 45.33M | 43M | 31.68M |
| OpEx % of Revenue | 59663.63% | 15405.12% | 2789.31% | 21.82% | 41.12% | 162.83% | 665.49% | 1098.23% | 5089.8% |
| Selling, General & Admin | 3.52M | 4.74M | 4.56M | 12.94M | 24.95M | 21.61M | 21.14M | 20.64M | 11.44M |
| SG&A % of Revenue | 45973.66% | 11867.45% | 2120.7% | 17.36% | 25.49% | 63.15% | 310.34% | 527.19% | 1837.69% |
| Research & Development | 1M | 1.36M | 1.37M | 3.19M | 14.96M | 17.44M | 22.96M | 20.98M | 19.14M |
| R&D % of Revenue | 13092.76% | 3410.47% | 637.95% | 4.27% | 15.29% | 50.96% | 337.09% | 535.86% | 3074.31% |
| Other Operating Expenses | 45.76K | 50.77K | 65.9K | 138.63K | 335.36K | 16.67M | 1.23M | 1.38M | 1.11M |
| Operating Income | -4.56M▲ 0% | -6.12M▼ 34.0% | -5.89M▲ 3.7% | 41.69M▲ 807.4% | 46.06M▲ 10.5% | -26.98M▼ 158.6% | -42.71M▼ 58.3% | -40.08M▲ 6.1% | -31.28M▲ 22.0% |
| Operating Margin % | -59567.57% | -15328.65% | -2741.61% | 55.93% | 47.06% | -78.85% | -626.92% | -1023.75% | -5025.53% |
| Operating Income Growth % | -170.39% | -34.04% | 3.66% | 807.42% | 10.48% | -158.57% | -58.29% | 6.15% | 21.95% |
| EBITDA | -4.52M | -6.07M | -5.83M | 41.83M | 46.4M | -25.7M | -41.48M | -38.7M | -30.18M |
| EBITDA Margin % | -58966.42% | -15201.45% | -2710.95% | 56.11% | 47.4% | -75.1% | -608.86% | -988.57% | -4847.72% |
| EBITDA Growth % | -173.74% | -34.29% | 3.94% | 817.8% | 10.92% | -155.38% | -61.4% | 6.68% | 22.03% |
| D&A (Non-Cash Add-back) | 46.06K | 50.77K | 65.9K | 138.63K | 335.36K | 1.28M | 1.23M | 1.38M | 1.11M |
| EBIT | -6.65M | -6.14M | -6.09M | 41.69M | 46.06M | -11.59M | -42.71M | -40.08M | -31.28M |
| Net Interest Income | -306.4K | -115.14K | -69.78K | 97.22K | 45.63K | 704.04K | 1.16M | 1.09M | 292.93K |
| Interest Income | 3.83K | 19.8K | 36.65K | 97.22K | 45.63K | 704.04K | 1.16M | 1.09M | 292.93K |
| Interest Expense | 310.23K | 134.95K | 106.44K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -2.4M | -153.91K | -301.82K | 875.42K | -429.16K | 8.13M | 4.6M | 2.5M | -17.23M |
| Pretax Income | -6.96M▲ 0% | -6.27M▲ 9.9% | -6.2M▲ 1.2% | 42.57M▲ 787.1% | 45.64M▲ 7.2% | -18.85M▼ 141.3% | -38.11M▼ 102.2% | -37.58M▲ 1.4% | -48.51M▼ 29.1% |
| Pretax Margin % | -90827.88% | -15714.27% | -2882% | 57.1% | 46.62% | -55.08% | -559.46% | -959.9% | -7793.22% |
| Income Tax | 0 | -18.96K | 0 | 90.54K | 8.98M | -4.61M | -2.78M | 57.37K | -1.62M |
| Effective Tax Rate % | 0% | 0.3% | 0% | 0.21% | 19.67% | 24.45% | 7.29% | -0.15% | 3.33% |
| Net Income | -6.96M▲ 0% | -6.27M▲ 9.9% | -6.2M▲ 1.2% | 42.48M▲ 785.6% | 36.66M▼ 13.7% | -14.24M▼ 138.8% | -35.33M▼ 148.2% | -37.64M▼ 6.5% | -46.9M▼ 24.6% |
| Net Margin % | -90827.88% | -15714.27% | -2882% | 56.98% | 37.45% | -41.61% | -518.68% | -961.37% | -7533.62% |
| Net Income Growth % | -260.83% | 9.88% | 1.21% | 785.63% | -13.7% | -138.84% | -148.15% | -6.53% | -24.59% |
| Net Income (Continuing) | -6.96M | -6.27M | -6.2M | 42.48M | 36.66M | -14.24M | -35.33M | -37.64M | -46.9M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -18.90▲ 0% | -15.00▲ 20.6% | -11.09▲ 26.1% | 1.52▲ 113.7% | 36.90▲ 2327.6% | -13.57▼ 136.8% | -36.00▼ 165.3% | -37.20▼ 3.3% | -35.25▲ 5.2% |
| EPS Growth % | -270.59% | 20.63% | 26.07% | 113.71% | 2327.63% | -136.78% | -165.29% | -3.33% | 5.24% |
| EPS (Basic) | -18.90 | -15.00 | -11.09 | 1.59 | 38.10 | -13.57 | -36.00 | -37.20 | -35.25 |
| Diluted Shares Outstanding | 365.34K | 416.15K | 558.56K | 933.35K | 996.79K | 1.05M | 978.22K | 1.01M | 1.33M |
| Basic Shares Outstanding | 365.34K | 416.15K | 558.56K | 890.67K | 962.49K | 1.05M | 978.22K | 1.01M | 1.33M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CODX Balance Sheet
Co-Diagnostics, Inc. (CODX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 4.45M | 1.05M | 1.58M | 68.36M | 115.12M | 92.73M | 62.14M | 32.29M | 13.69M |
| Cash & Short-Term Investments | 3.53M | 950.24K | 893.14K | 47.31M | 89.86M | 81.26M | 58.55M | 29.75M | 11.88M |
| Cash Only | 3.53M | 950.24K | 893.14K | 42.98M | 88.61M | 22.97M | 14.92M | 2.94M | 11.88M |
| Short-Term Investments | 0 | 0 | 0 | 4.34M | 1.26M | 58.29M | 43.63M | 26.81M | 0 |
| Accounts Receivable | 0 | 13.42K | 131.38K | 12.14M | 20.91M | 5.4M | 330.88K | 132.57K | 190.38K |
| Days Sales Outstanding | - | 122.73 | 223.07 | 59.42 | 77.99 | 57.59 | 17.73 | 12.36 | 111.63 |
| Inventory | 9.07K | 18.15K | 197.17K | 8M | 2M | 5.31M | 1.66M | 1.07M | 992.4K |
| Days Inventory Outstanding | 10.96K | 705.55 | 640.09 | 175.89 | 63.2 | 353.64 | 145.19 | 391.89 | 1.63K |
| Other Current Assets | 0 | 0 | 0 | 547.22K | 0 | 0 | 1.6M | 0 | 626.09K |
| Total Non-Current Assets | 210.45K | 501.26K | 631.07K | 2.88M | 44.91M | 30.35M | 33.18M | 31.71M | 11.05M |
| Property, Plant & Equipment | 165.57K | 156.14K | 196.83K | 949.64K | 1.93M | 2.91M | 6M | 4.88M | 3.48M |
| Fixed Asset Turnover | 0.05x | 0.26x | 1.09x | 78.51x | 50.63x | 11.75x | 1.13x | 0.80x | 0.18x |
| Goodwill | 0 | 0 | 0 | 0 | 14.71M | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 27.2M | 26.77M | 26.4M | 26.1M | 7.22M |
| Long-Term Investments | 44.88K | 345.12K | 434.24K | 1.93M | 1M | 672.68K | 773.38K | 731.07K | 350.57K |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 75K | 0 | 0 | 0 | 0 |
| Total Assets | 4.66M▲ 0% | 1.55M▼ 66.7% | 2.22M▲ 42.6% | 71.24M▲ 3115.7% | 160.03M▲ 124.6% | 123.09M▼ 23.1% | 95.32M▼ 22.6% | 64M▼ 32.9% | 24.74M▼ 61.3% |
| Asset Turnover | 0.00x | 0.03x | 0.10x | 1.05x | 0.61x | 0.28x | 0.07x | 0.06x | 0.03x |
| Asset Growth % | 259.8% | -66.69% | 42.63% | 3115.65% | 124.65% | -23.09% | -22.56% | -32.86% | -61.34% |
| Total Current Liabilities | 628.26K | 2.35M | 328.07K | 4.06M | 12.6M | 3.87M | 5.75M | 7.32M | 3.54M |
| Accounts Payable | 40.82K | 148.97K | 5.96K | 598.32K | 607.51K | 952.3K | 1.48M | 3.29M | 1.88M |
| Days Payables Outstanding | 49.33K | 5.79K | 19.35 | 13.16 | 19.16 | 63.42 | 129.27 | 1.2K | 3.08K |
| Short-Term Debt | 0 | 1.91M | 0 | 0 | 0 | 0 | 0 | 0 | 662.26K |
| Deferred Revenue (Current) | 10.79K | 0 | 1.32K | 305.31K | 150K | 0 | 362.45K | 0 | 14.8K |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 5.77M | 1.69M | 1.42M | 543.68K | 984.34K |
| Current Ratio | 7.09x | 0.45x | 4.83x | 16.83x | 9.14x | 23.94x | 10.81x | 4.41x | 3.87x |
| Quick Ratio | 7.07x | 0.44x | 4.23x | 14.86x | 8.98x | 22.57x | 10.52x | 4.27x | 3.59x |
| Cash Conversion Cycle | - | -4.96K | 843.82 | 222.15 | 122.03 | 347.81 | 33.66 | -799.21 | -1.34K |
| Total Non-Current Liabilities | 183.55K | 260K | 150K | 477.83K | 12.96M | 4.69M | 3.56M | 2.37M | 574.3K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 574.3K |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 50.71K | 2.15M | 1.24M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 7.23M | 2.42M | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 260K | 150K | 477.83K | 5.73M | 2.22M | 1.41M | 1.14M | 0 |
| Total Liabilities | 811.8K | 2.61M | 478.07K | 4.54M | 25.56M | 8.57M | 9.31M | 9.69M | 4.11M |
| Total Debt | 0 | 1.91M | 0 | 0 | 0 | 347.92K | 2.99M | 2.15M | 1.24M |
| Net Debt | -3.53M | 958.34K | -893.14K | -42.98M | -88.61M | -22.63M | -11.93M | -784.37K | -10.65M |
| Debt / Equity | - | - | - | - | - | 0.00x | 0.03x | 0.04x | 0.06x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | -1.03x | -1.91x | - | - | - | - |
| Interest Coverage | -21.43x | -45.48x | -57.21x | - | - | - | - | - | - |
| Total Equity | 3.85M▲ 0% | -1.06M▼ 127.5% | 1.74M▲ 264.1% | 66.7M▲ 3739.2% | 134.48M▲ 101.6% | 114.52M▼ 14.8% | 86.01M▼ 24.9% | 54.31M▼ 36.9% | 20.63M▼ 62.0% |
| Equity Growth % | 228.58% | -127.5% | 264.08% | 3739.19% | 101.62% | -14.84% | -24.89% | -36.86% | -62.02% |
| Book Value per Share | 10.54 | -2.54 | 3.11 | 71.46 | 134.91 | 109.14 | 87.93 | 53.71 | 15.51 |
| Total Shareholders' Equity | 3.85M | -1.06M | 1.74M | 66.7M | 134.48M | 114.52M | 86.01M | 54.31M | 20.63M |
| Common Stock | 12.32K | 12.92K | 17.34K | 28.56K | 33.82K | 34.75K | 36.11K | 37.9K | 67.7K |
| Retained Earnings | -12.42M | -18.69M | -24.97M | 17.51M | 54.17M | 39.93M | 4.6M | -33.04M | -80.37M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | -14.21M | -15.58M | -15.58M | -15.58M |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 293.14K | 146.7K | 418.44K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CODX Cash Flow Statement
Co-Diagnostics, Inc. (CODX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -3.21M | -4.08M | -5.53M | 28.17M | 41.08M | 6.57M | -22.08M | -29.16M | -29.14M |
| Operating CF Margin % | -41913.35% | -10222.84% | -2570.12% | 37.78% | 41.97% | 19.2% | -324.16% | -744.67% | -4680.71% |
| Operating CF Growth % | -144.72% | -27.05% | -35.42% | 609.77% | 45.86% | -84.01% | -436.17% | -32.03% | 0.06% |
| Net Income | -6.96M | -6.27M | -6.2M | 42.48M | 36.66M | -14.24M | -35.33M | -37.64M | -46.9M |
| Depreciation & Amortization | 45.76K | 50.77K | 65.9K | 138.63K | 335.36K | 1.28M | 1.23M | 1.38M | 1.11M |
| Stock-Based Compensation | 2.03M | 1.33M | 1.09M | 2.74M | 5.51M | 7.54M | 8.34M | 5.43M | 2.25M |
| Deferred Taxes | 0 | 0 | 243.03K | -547.22K | 930.08K | -4.81M | -2.42M | 0 | 0 |
| Other Non-Cash Items | 2.17M | 38.76K | 91.43K | 176.59K | 544.46K | 10.6M | 460.32K | -1.08M | 17.57M |
| Working Capital Changes | -504.75K | 769.77K | -818.28K | -16.82M | -2.9M | 6.19M | 5.64M | 2.75M | -3.17M |
| Change in Receivables | -698.39K | -13.42K | -121.46K | -12.96M | -8.74M | 14.92M | 2.54M | 186.39K | -31.8K |
| Change in Inventory | -9.07K | -9.09K | -179.01K | -7.92M | 5.71M | -3.67M | 413.14K | 265.49K | 131.27K |
| Change in Payables | 8.37K | 85.95K | -226.66K | 3.76M | -299.94K | -2.48M | 1.77M | 2.16M | -3.11M |
| Cash from Investing | -189.31K | -380.34K | -435.25K | -5.82M | 4.1M | -58.17M | 15.39M | 17.07M | 26.27M |
| Capital Expenditures | -129.31K | -41.34K | -113.25K | -774.4K | -669.46K | -1.43M | -1.37M | -748.35K | -700.05K |
| CapEx % of Revenue | 1687.63% | 103.57% | 52.68% | 1.04% | 0.68% | 4.17% | 20.04% | 19.11% | 112.46% |
| Acquisitions | 0 | 0 | -322K | -714.5K | 1.69M | 0 | 0 | -143.75K | -102.57K |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -322K | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 5.94M | 1.88M | 5.9M | 19.74M | 450.4K | -14.03M | -1.36M | 103.91K | 11.81M |
| Debt Issued (Net) | -41.5K | 2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 7.07M | 30K | 6.5M | 19.47M | 450.4K | -14.21M | -1.36M | 103.91K | 11.81M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -14.21M | -1.36M | 0 | 0 |
| Other Financing | -1.09M | -153.84K | -592.76K | 272.68K | 0 | 177.87K | 0 | 0 | 0 |
| Net Change in Cash | 2.54M▲ 0% | -2.58M▼ 201.9% | -57.1K▲ 97.8% | 42.08M▲ 73802.8% | 45.63M▲ 8.4% | -65.63M▼ 243.8% | -8.06M▲ 87.7% | -11.98M▼ 48.7% | 8.95M▲ 174.7% |
| Free Cash Flow | -3.34M▲ 0% | -4.12M▼ 23.4% | -5.64M▼ 36.8% | 27.39M▲ 585.8% | 40.41M▲ 47.5% | 5.14M▼ 87.3% | -23.45M▼ 556.1% | -29.9M▼ 27.5% | -29.84M▲ 0.2% |
| FCF Margin % | -43600.98% | -10326.41% | -2622.8% | 36.74% | 41.28% | 15.02% | -344.2% | -763.78% | -4793.17% |
| FCF Growth % | -152.22% | -23.37% | -36.81% | 585.8% | 47.54% | -87.28% | -556.06% | -27.54% | 0.22% |
| FCF per Share | -9.14 | -9.90 | -10.09 | 29.35 | 40.54 | 4.90 | -23.97 | -29.57 | -22.43 |
| FCF Conversion (FCF/Net Income) | 0.46x | 0.65x | 0.89x | 0.66x | 1.12x | -0.46x | 0.62x | 0.77x | 0.62x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 5.4M | 4.5M | 55.98K | 0 | 858.87K |
CODX Key Ratios
Co-Diagnostics, Inc. (CODX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -1626.11% | -449.31% | -1826.4% | 124.14% | 36.45% | -11.44% | -35.24% | -53.65% | -125.16% |
| Return on Invested Capital (ROIC) | - | - | -4256.48% | -1188.83% | 254.6% | 99.3% | -29.38% | -38.59% | -47.11% | -73.89% |
| Gross Margin | - | 96.06% | 76.47% | 47.7% | 77.75% | 88.17% | 83.98% | 38.57% | 74.48% | 64.28% |
| Net Margin | - | -90827.88% | -15714.27% | -2882% | 56.98% | 37.45% | -41.61% | -518.68% | -961.37% | -7533.62% |
| Debt / Equity | - | - | - | - | - | - | 0.00x | 0.03x | 0.04x | 0.06x |
| Interest Coverage | -7.01x | -21.43x | -45.48x | -57.21x | - | - | - | - | - | - |
| FCF Conversion | 0.68x | 0.46x | 0.65x | 0.89x | 0.66x | 1.12x | -0.46x | 0.62x | 0.77x | 0.62x |
| Revenue Growth | -100% | - | 420.9% | 438.63% | 34579.9% | 31.3% | -65.04% | -80.09% | -42.53% | -84.1% |
CODX SEC Filings & Documents
Co-Diagnostics, Inc. (CODX) SEC filings — annual & quarterly reports (10-K, 10-Q)
CODX Frequently Asked Questions
Co-Diagnostics, Inc. (CODX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Co-Diagnostics, Inc. (CODX) reported $0.6M in revenue for fiscal year 2025.
Co-Diagnostics, Inc. (CODX) saw revenue decline by 84.1% over the past year.
Co-Diagnostics, Inc. (CODX) reported a net loss of $46.9M for fiscal year 2025.
Dividend & Returns
Co-Diagnostics, Inc. (CODX) has a return on equity (ROE) of -125.2%. Negative ROE indicates the company is unprofitable.
Co-Diagnostics, Inc. (CODX) had negative free cash flow of $29.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More CODX
Co-Diagnostics, Inc. (CODX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates